These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas. Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816 [TBL] [Abstract][Full Text] [Related]
3. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411 [TBL] [Abstract][Full Text] [Related]
11. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma. Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213 [TBL] [Abstract][Full Text] [Related]
14. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Kato Kaneko M; Ogasawara S; Kato Y Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684 [TBL] [Abstract][Full Text] [Related]
15. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia. Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876 [TBL] [Abstract][Full Text] [Related]
16. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome. Glöss S; Jurmeister P; Thieme A; Schmid S; Cai WY; Serrette RN; Perner S; Ribbat-Idel J; Pagenstecher A; Bläker H; Keber U; Stadelmann C; Zechel S; Johann PD; Hasselblatt M; Paulus W; Thomas C; Dohmen H; Baumhoer D; Frank S; Agaimy A; Schüller U; Vasudevaraja V; Snuderl M; Liu CZ; Pfister DG; Jungbluth AA; Ghossein RA; Xu B; Capper D; Dogan S Am J Surg Pathol; 2021 Sep; 45(9):1190-1204. PubMed ID: 34265800 [TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. Horbinski C; Kofler J; Kelly LM; Murdoch GH; Nikiforova MN J Neuropathol Exp Neurol; 2009 Dec; 68(12):1319-25. PubMed ID: 19915484 [TBL] [Abstract][Full Text] [Related]